Cancer drugs are increasingly designed to target specific cell-signalling pathways. When, and in what combination, these drugs should be used might be judged by analysing the gene expression signature of the tumour.
This is a preview of subscription content, log in via an institution to check access.
References
Solit, D. B. et al. Nature 439, 358–362 (2006).
Bild, A. H. et al. Nature 439, 353–357 (2006).
Weinstein, I. B. Science 297, 63–64 (2002).
Downward, J. Nature Rev. Cancer 3, 11–22 (2003).
Mao, J. H. et al. Genes Dev. 18, 1800–1805 (2004).
Sebolt-Leopold, J. S. & Herrera, R. Nature Rev. Cancer 4, 937–947 (2004).
Neiman, P. E. et al. Proc. Natl Acad. Sci. USA 98, 6378–6383 (2001).
Huang, E. et al. Nature Genet. 34, 226–230 (2003).
Pavey, S. et al. Oncogene 23, 4060–4067 (2004).
Sweet-Cordero, A. et al. Nature Genet. 37, 48–55 (2005).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Downward, J. Signatures guide drug choice. Nature 439, 274–275 (2006). https://doi.org/10.1038/439274a
Published:
Issue Date:
DOI: https://doi.org/10.1038/439274a
- Springer Nature Limited
This article is cited by
-
Increased baseline RASGRP1 signals enhance stem cell fitness during native hematopoiesis
Oncogene (2020)
-
ANT2 suppression by shRNA restores miR-636 expression, thereby downregulating Ras and inhibiting tumorigenesis of hepatocellular carcinoma
Experimental & Molecular Medicine (2013)
-
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells
British Journal of Cancer (2012)
-
Embryonic stem cell-specific signatures in cancer: insights into genomic regulatory networks and implications for medicine
Genome Medicine (2011)
-
A pharmacogenomic method for individualized prediction of drug sensitivity
Molecular Systems Biology (2011)